Excelsior Sciences Raises $95M to Accelerate AI‑Enabled, Machine‑Executable Small Molecule Discovery
Excelsior Sciences, a New York–based biotechnology company developing machine‑executable chemistry and AI‑enabled systems to transform the way small molecules are discovered and manufactured, has raised $95 million in a major funding round aimed at accelerating its mission to cut years off traditional drug discovery and production timelines. The financing includes a substantial $70 million Series A investment co‑led by some of the industry’s most respected life sciences investors, alongside additional public support intended to bolster reshoring and domestic pharmaceutical capability.
The Series A round was co‑led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, reflecting strong confidence in Excelsior’s novel approach to small‑molecule science and automated chemistry. Other participants in the financing include Cornucopian Capital, Eli Lilly and Company, Illinois Ventures, and leading academic institutions such as MIT, all of which are contributing both capital and strategic validation as the company moves toward deployment of its pioneering technology. In addition to the venture funding, Excelsior secured a $25 million grant from New York’s Empire State Development to support its growth and development in the U.S. biotech hub.
Excelsior Sciences’ platform centers on proprietary “smart bloccs”, a modular chemical building block approach that enables automated synthesis in a way that traditional small‑molecule chemistry cannot. These smart bloccs serve as building units that machines can efficiently assemble, allowing artificial intelligence to iterate rapidly through chemical designs and optimize potential drug candidates in a closed‑loop system. By combining machine‑friendly chemistry with powerful AI guidance, the company aims to significantly shorten the cycle of discovery, synthesis, and testing that has long slowed the creation of new small‑molecule therapeutics.
Small molecules remain foundational in medicine and materials science, comprising a majority of drugs approved by regulatory agencies such as the U.S. Food and Drug Administration. However, their development traditionally involves labor‑intensive synthesis processes that can take years and cost billions of dollars. Excelsior’s smart bloccs and AI‑ready chemistry are designed to replace these artisanal methods with a scalable, automated system that not only accelerates discovery but also supports scalable manufacturing. With the new funding, the company intends to increase its internal pipeline work, expand its smart bloccs libraries, and develop partnerships across a range of industries including therapeutics, agriculture, and materials.
CEO and co‑founder Michael Foley, Ph.D., explained that the fusion of machine‑executable chemistry with AI guidance could reshape how new molecules are created by enabling tighter integration between design and synthesis. Rather than relying on decades‑old techniques that require expert intervention at every step, Excelsior’s system uses smart bloccs to allow autonomous chemistry platforms to produce and test compounds in rapid succession, generating the high‑quality datasets needed to train and refine AI models. Excelsior believes this capability will not only speed drug discovery but also support the reshoring of critical pharmaceutical manufacturing to the United States at a time when global supply chains face strategic pressures.
Investor enthusiasm for Excelsior’s approach reflects broader trends in biotechnology and artificial intelligence, where the integration of automated systems and machine learning is seen as a key competitive advantage. By reducing the time between molecule design and production, the company’s platform could allow researchers and developers to explore chemical space far more efficiently than traditional methods permit. In addition to therapeutic development, this capability has potential applications in materials science, crop protection, and other fields where rapid synthesis of small molecules can unlock new innovations.
The inclusion of strategic partners such as Eli Lilly and Company and academic collaborators like MIT underscores the depth of interest in Excelsior’s technology from both industry and research communities. These partnerships are expected to help guide practical applications of the smart bloccs platform and integrate Excelsior’s automated chemistry tools into broader discovery pipelines that span university research, biotech startups, and established pharmaceutical firms.
With its substantial Series A funding and grant support, Excelsior Sciences is well positioned to scale its novel chemistry platform, grow its scientific and engineering teams, and drive toward commercial proof‑points that demonstrate the power of AI‑enabled, machine executable small‑molecule innovation. As the company progresses, it aims to help redefine the economics and timelines of drug discovery and materials development in the era of AI‑augmented science.
